Abstract
Clinical trials have left little doubt that in patients with symptoms of acute myocardial infarction, early reperfusion achieved with coronary thrombolytic therapy is beneficial in limiting infarct size [ 1 Koren G. Weiss A.T. Hasin Y. et al. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N Eng J Med. 1985; 313: 1384-1389 Google Scholar , 2 Hasche E.T. Fernandes C. Freedman S.B. Jeremy R.W. Relation between ischemia time, infarct size and left ventricular function in humans. Circulation. 1995; 92: 710-719 Google Scholar , 3 Raitt M.H. Maynard C. Wagner G.S. Cerqueira M.D. Silvester R.H. Weaver W.D. Relation between symptom duration before thrombolytic therapy and final myocardial infarct size. Circulation. 1996; 93: 48-53 Google Scholar , 4 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349–360. Google Scholar ].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
